---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Epithelial sodium channel blockers"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Epithelial sodium channel blockers. Topics: Amiloride when mineralocorticoid receptor antagonists are not tolerated: 2025 AHA/ACC guideline, Amiloride as an alternative to spironolactone: 2024 ESC guideline, Amiloride dosing and availability: 2023 ESH guideline, Amiloride open-label runout: PATHWAY-2 mechanisms substudy, and 4 further topics. 8 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description/epithelial-sodium-channel-blockers"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Epithelial sodium channel blockers

<a id="heading-2.2.2.1.4"></a>

## 2.2.2.1.4 Epithelial Sodium Channel Blockers

<a id="topic-2.2.2.1.4-1"></a>

### Amiloride when mineralocorticoid receptor antagonists are not tolerated: 2025 AHA/ACC guideline

> “When spironolactone or eplerenone are not tolerated due to side effects or cost, amiloride (10-20 mg) has been shown to be as effective as spironolactone in adults with resistant hypertension.”
> “As monotherapy, these agents are minimally effective antihypertensive agents. Combination therapy of a potassium-sparing diuretic with a thiazide-type diuretic can be considered in patients with hypokalemia on thiazide-type diuretic monotherapy. Avoid use in patients with significant CKD (eg, GFR <45 mL/min).”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.2.1.4-2"></a>

### Amiloride as an alternative to spironolactone: 2024 ESC guideline

> “Amiloride and clonidine have data suggesting they are as effective as spironolactone for BP lowering, though they lack outcomes data.”

Source: [McEvoy et al. (2024)](https://academic.oup.com/eurheartj/article/45/38/3912/7741010)

<a id="topic-2.2.2.1.4-3"></a>

### Amiloride dosing and availability: 2023 ESH guideline

> “Alternative drugs can be amiloride, to be used at high dosages (10– 20 mg per day), which was as effective as spironolactone (25– 50 mg per day) in reducing BP in an open-label extension period of the PATHWAY-2 trial”
> “However, this can lead to an increased pill burden as the marketed dose of amiloride is only 5 mg, and the drug is not available as a single agent but only in combinations (usually 5 mg) in many countries.”

Source: [Mancia et al. (2023)](https://journals.lww.com/jhypertension/fulltext/2023/12000/2023_esh_guidelines_for_the_management_of_arterial.2.aspx)

<a id="topic-2.2.2.1.4-4"></a>

### Amiloride open-label runout: PATHWAY-2 mechanisms substudy

> “assessed the effect of amiloride 10–20 mg once daily on clinic systolic blood pressure during an optional 6–12 week open-label runout phase (substudy 3).”
> “Amiloride (10 mg once daily) reduced clinic systolic blood pressure by 20·4 mm Hg (95% CI 18·3–22·5), compared with a reduction of 18·3 mm Hg (16·2–20·5) with spironolactone (25 mg once daily). No serious adverse events were recorded, and adverse symptoms were not systematically recorded after the end of the double-blind treatment. Mean plasma potassium concentrations increased from 4·02 mmol/L (95% CI 3·95–4·08) on placebo to 4·50 (4·44–4·57) on amiloride (p<0·0001).”

Source: [Williams et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5966620/)

<a id="topic-2.2.2.1.4-5"></a>

### Amiloride versus spironolactone: randomized noninferiority trial

> “Prospective, open-label, blinded end-point randomized clinical trial conducted at 14 sites in South Korea. From November 16, 2020, to February 29, 2024, 118 patients with home SBP of 130 mm Hg or greater after a 4-week run-in period with a fixed-dose triple medication combination (angiotensin receptor blocker, calcium channel blocker, and thiazide) were enrolled.”
> “Patients were randomized in a 1:1 ratio to receive 12.5 mg/d of spironolactone (n = 60) or 5 mg/d of amiloride (n = 58). If home SBP remained 130 mm Hg or greater and serum potassium was less than 5.0 mmol/L after 4 weeks, dosages were increased to 25 mg/d and 10 mg/d, respectively.”
> “At week 12, mean home SBP measurements were changed from baseline by −13.6 (SD, 8.6) mm Hg and −14.7 (SD, 11.0) mm Hg in the amiloride and spironolactone groups, respectively (between-group difference in change, −0.68 mm Hg; 90% CI, −3.50 to 2.14 mm Hg), with amiloride demonstrating noninferiority to spironolactone.”
> “One case of hyperkalemia-related discontinuation occurred in the amiloride group, with no cases of gynecomastia in either group.”

Source: [Lee et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12079568/)

<a id="topic-2.2.2.1.4-6"></a>

### Amiloride trial limitations: dose and kidney function

> “First, we did not compare the efficacy of higher doses of spironolactone (50 mg vs 20 mg), as used in the PATHWAY-2 trial.”
> “Second, we excluded participants with an estimated glomerular filtration rate of less than 50 mL/min/1.73 m2; hence, our results may not be generalizable to patients with chronic kidney disease.”

Source: [Lee et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12079568/)

<a id="topic-2.2.2.1.4-7"></a>

### Amiloride hyperkalemia warning: ICER evidence report

> “While rates associated with amiloride treatment were unavailable, amiloride has an FDA boxed warning for hyperkalemia, either alone or in combination with hydrochlorothiazide.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-2.2.2.1.4-8"></a>

### Generic amiloride costs: ICER evidence report

| Drug | WAC per dose | Net price per year |
| --- | --- | --- |
| Amiloride 5 mg | “$0.5627” | “$206” |
| Amiloride 10 mg | “$1.1253” | “$411” |

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
